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Abstract
Left ventricular hypertrophy (LVH) is associated with decreased responsiveness of renal α1-
adrenoreceptors subtypes to adrenergic agonists. Nitric oxide donors are known to have
antihypertrophic effects however their impact on responsiveness of renal α1-adrenorecep-
tors subtypes is unknown. This study investigated the impact of nitric oxide (NO) and its
potential interaction with the responsiveness of renal α1-adrenoreceptors subtypes to adren-
ergic stimulation in rats with left ventricular hypertrophy (LVH). This study also explored the
impact of NO donor on CSE expression in normal and LVH kidney. LVH was induced using
isoprenaline and caffeine in drinking water for 2 weeks while NO donor (L-arginine, 1.25g/
Lin drinking water) was given for 5 weeks. Intrarenal noradrenaline, phenylephrine and
methoxamine responses were determined in the absence and presence of selective α1-
adrenoceptor antagonists, 5- methylurapidil (5-MeU), chloroethylclonidine (CeC) and BMY
7378. Renal cortical endothelial nitric oxide synthase mRNA was upregulated 7 fold while
that of cystathione γ lyase was unaltered in the NO treated LVH rats (LVH-NO) group com-
pared to LVH group. The responsiveness of renal α1A, α1B and α1D-adrenoceptors in the low
dose and high dose phases of 5-MeU, CEC and BMY7378 to adrenergic agonists was
increased along with cGMP in the kidney of LVH-NO group. These findings suggest that
exogenous NO precursor up-regulated the renal eNOS/NO/cGMP pathway in LVH rats and
resulted in augmented α1A, α1B and α1D adrenoreceptors responsiveness to the adrenergic
agonists. There is a positive interaction between H2S and NO production in normal animals
but this interaction appears absent in LVH animals.
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Introduction
Left ventricular hypertrophy (LVH) is characterized by overstimulation of the heart due to
hyperactivity of the sympathetic nervous system and both circulating noradrenaline and mean
discharge frequency in peripheral sympathetic nerves have been reported elevated in hyperten-
sive LVH patients [1].At an experimental level, renal sympathetic nerve activity was found to
be elevated in rats with essential hypertension and LVH compared to the control Wistar Kyoto
rats [2]. This sympatho-activation is associated with vascular dysfunction and impairment of
α1-adrenoceptor-mediated renal vasoconstriction [3].This attenuation of α1-adrenoceptor-
mediated renal vasoconstrictor responsiveness to adrenergic agonists in states of hypertension
and renal failure has been studied previously [4]. Moreover, a decrease in responsiveness of
α1D–adrenoreceptors to adrenergic agonists when administered exogenously has been
reported LVH [5]. However, the question of the role of NO on the responsiveness of α1-adre-
noceptors in LVH remains unanswered.
Higher levels of noradrenaline (NA) and angiotensin II (Ang II) in the plasma have been
found in rat models of LVH induced using isoprenaline and caffeine [5–7] At the level of renal
vasculature, catecholamines are released at the sympathetic nerve neuro-effector junctions and
activate the G-protein operated adrenoreceptors which increase cytosolic Ca2+ concentration
to vascular smooth muscle contractions [8]. Pharmacological and cloning studies have
reported three subtypes of α1-adrenoceptors, α1A, α1B and α1D [9]. These α1-adrenoceptors are
operated by G-protein coupled receptor 2nd messenger signalling pathway [9]. Increased vaso-
constriction due to elevated NA and Ang II can be suppressed as a result of an up-regulation
of the NO-cGMP pathway which is responsible for inhibition of L-type Ca2+ channels [10]
which induce a vasodilation.
Nitric oxide derived from endothelial nitric oxide synthase (eNOS) is important in main-
taining and determining normal renal hemodynamic and tubular reabsorptive function [11,
12]. Nitric oxide has been reported to reduce renal ischemia reperfusion injury [13] both
directly and indirectly [14].There is evidence demonstrating that NO exerts a tonic role in the
medullary circulation [15] where it seems to have a higher concentration than in the cortex
[16]. Earlier studies have shown that intravenous infusion of endothelial cells (eNOS) in ische-
mic kidney provides dramatic renoprotection by lowering plasma creatinine [17, 18]. We
reported recently that the down regulation of the eNOS/NO pathway was associated with a
decrease in responsiveness of α1A–adrenoreceptors to adrenergic agonists in the kidney of
LVH rats [19]. Decreased responsiveness of α1-adrenoreceptors has been reported in many
pathological conditions such as hypertension and renal failure [4], in fructose fed rats and in
LVH [5]. Although these studies provide an elegant insight as to the renal consequences of
reduced responsiveness of α1-adrenoceptors to adrenergic agonists, no study has been con-
ducted to determine the impact of an increase in the responsiveness of α1-adrenoreceptors in
different pathological conditions.
Various studies have shown that production of both H2S and NO are interdependent [20–
24] in regulating vascular tone. Literature showed that H2S yield NO production in smooth
muscles [25,26] while it has also been reported that NO enhanced the up regulation of H2S
production as reflected by plasma concentrations [27, 28].
The potential interaction between NO and α1–adrenoceptor subtypes of normal or LVH
animals in regulating renal hemodynamic has not been investigated to date. Collectively, the
evidence available regarding NO plus our recent findings of an interaction between eNOS/NO
α1–adrenorecptors subtypes in the kidney of LVH rats raises a number of questions. The
hypothesis to be explored is as follows: firstly, that upregulation of the eNOS/NO/cGMP path-
way will increase the responsiveness of the renal vascular α1–adrenoreceptor subtypes to
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adrenergic agonists in LVH rats; secondly, that up regulation of eNOS/NO in kidney will
improve renal cortical blood perfusion in LVH; thirdly, that chronic administration of L-argi-
nine (an NO donor) will suppress the CSE/H2S pathway in the kidney of LVH rats.
Materials and methods
Animals and induction of LVH
All the procedures of current study were approved by the Animal Research and Service Centre
(ARASC) USM with approval no./2012/ (76) (364) and all the methods were performed by the
guidelines and procedures as approved by ARASC. 84 male Wistar Kyoto (WKY) rats (200
±10g) were recruited from the animal house of Universiti Sains Malaysia and kept in standard
animal facility provided by School of Pharmaceutical Sciences, USM with free access to food
and water. All animals were divided into three main groups; one for renal functional studies, a
second group for CSE and eNOS mRNA evaluation and a third group for the measurement of
nitric oxide synthase (NOS) protein expression. The main group for renal hemodynamic func-
tional examination of α1-adrenoceptors subtypes consisted of 12 subgroups groups. These
groups were named according to antagonists used in that group. Renal functional study group
consists of:
(1) Control-5MeU; (2) Control-CEC; (3) Control-BMY. LVH groups consisted of: (4)
LVH-5MeU; (5) LVH-CEC; (6) LVH-BMY. Control groups treated with NO consisted of: (7)
Control-NO+5MeU; (8) Control-NO+ CEC; (9) Control-NO+BMY.LVH groups treated with
NO consisted of: (10) LVH-NO+5MeU: (11) LVH-NO+CEC; (12) LVH-NO+BMY (n = 6).
Similarly, molecular study for quantification of CSE and eNOS mRNA expression consisted of
4 groups: Control, LVH, Control-NO and LVH-NO whereby the cortex part of left kidneys
were taken for quantification of CSE and eNOS mRNAs expression. A third group, Control
(Control-L-NIO) and a LVH group (LVH-L-NIO),which received L-N5-(1-iminoethyl)-orni-
thine), (10mg/kg I.P.) 15 minutes before the acute experiment [29] and NOS activity was com-
pared to a control group (control-L-NIO).
LVH was induced by a modification of an earlier model [30] using isoprenaline (5mg/kg s.
c) and caffeine as recently reported [5].Control-NO and LVH-NO group rats received L-argi-
nine (1.25 g/L in the drinking water) was used as a donor of NO for 5 weeks as reported previ-
ously [31]. Control rats received i.ps injection of 0.9% NaCl.
Molecular expression of CSE and eNOSmRNAs in the cortex of the kidney
Molecular expression study was performed following the procedure reported earlier [19].
Conversion of RNA to cDNA was performed by using a High Capacity RNA-to-cDNA kit
(Applied Biosystems™, USA) according to the manufacturer’s instruction.
Different TaqMan primers and probes were used for gene which have following accession
numbers; CSE gene (Gen Bank accession No. NM_017074.1 and Rn00567128_m1) [32];
eNOS genes (Gen Bank accession No. NM_021838.2 and Rn02132634_s1) [33, 34] and for the
β-actingene (Gen Bank accession No. NM_031144.2 and Rn00667869_m1) were derived from
TaqMan1-Gene Expression assays (Applied Biosystems, USA) [35, 36].TaqMan1 Gene
Expression assays were obtained and the procedure was followed according to the instructions
of the manufacturer (Applied Biosystems™, USA).
Quantitative RT-PCR reactions were carried out on cortex of the left kidney. Amplification
of the housekeeping enzyme (internal control) Beta actin allowed sample loading and normali-
zation to be determined. The relative quantification of the target genes CSE, eNOS and inter-
nal control beta actin used the comparative CT (threshold cycle) method with arithmetic
formula (2-ΔΔCT) [37].
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NOS enzyme activity in kidney
NOS enzyme activity was done as reported in earlier studies [38, 39]. Enzyme activity was
expressed as citrulline production in femtomol per milligram of protein per minute.
Measurement of nitric oxide concentration in the plasma and kidney
The plasma and tissue concentration of nitric oxide was measured using kits as directed by
manufacturer (NJJC Bio Inc., Nanjing, China) while protein quantity was measured using an
early reported method [39, 40]. Blood was collected from the rat and centrifuged at 5000g for
10 minutes to collect plasma for analysis of nitric oxide.
Measurement of hydrogen sulphide concentration in the plasma
The plasma concentration of H2S was measured as reported previously [41, 42].
Measurement of cGMP levels in the kidney
The method used followed the instructions provided by manufacture of the cGMP Direct
Immunoassay Kit (Abcam). However, procedure involves sample preparation, construction of
standard curve, followed by acylation and then quantification of cGMP by measuring the opti-
cal density at 450nm.
Acute experiment for renal vasoconstrictor responses
In vivo renal vasoconstrictor responses studies were performed as previously reported [43].
Animals were anaesthetized by intraperitoneal pentobarbitone sodium (60mg/kg, Nembu-
tal1, CEVA, France) injections. Tracheotomy was done by inserting tubing in the trachea to
facilitate breathing followed by cannulation of jugular vein and carotid artery for vehicle infu-
sion and continuous MAP monitoring respectively. Furthermore, carotid artery cannula was
connected to a pressure transducer (model P23 ID Gould, Statham Instruments, UK) which
was further attached to a PowerLab data acquisition system (PowerLab, ADInstruments, Aus-
tralia). A mid-line abdominal incision was made to expose the aorta and left kidney and a laser
Doppler probe (ADInstruments, Australia) was placed on the cortical surface of the left kidney
to measure renal cortical blood perfusion (RCBP). In order to facilitate the close infusion of
adrenergic agonist noradrenaline (NA), phenylephrine (PE) and methoxamine (ME) close to
the face of renal artery, left iliac artery was cannulated and cannula was pushed at the required
level designed by study [44, 45]. Animals were allowed to stabilize for 1 hour before commenc-
ing acute vasoconstrictor studies.
Renal vasoconstrictor responses
Different doses of NA, PE and ME were administered intrarenally in ascending and descend-
ing order as described below; NA at 25, 50, 100 and 200ng; PE at 0.25, 0.5,1 and 2μg; ME at 1,
2, 3 and 4 μg. These drugs were prepared in saline (0.9g of NaCl/L of water) freshly every day
and stored in 4˚C [42, 46]. A wash out time of 10 min was given to each dose administered to
ensure washout of agonists [47, 48]. Overall acute experiment consisted of three phases, a
saline or non-drug phase, a low dose antagonist phase and a high dose antagonist phase. In the
saline phase, saline was infused intrarenally at a rate of 6ml/kg/h during which adrenergic ago-
nists were infused in ascending and descending order. In the low and high dose phases,
5-MeU was administered close to renal artery at bolus dose of 5μg/kg and plus infusion of 1/
4th of the bolus dose as a continuous infusion (1.5μg/kg/h) to study α1Aadrenoreceptors while
during the high dose phase 5-MeU was administered as a 10μg/kg bolus dose followed by a
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continuous infusion of 2.5μg/kg/h. Chloroethylclonidine was administered in low dose (5mg/
kg as bolus dose) and high dose (10 mg/kg as bolus) in kidney [49]. BMY 7378 was infused
intrarenally at 100 and 200mg/kg plus 1/4th the dose as a continuous infusion, for the low and
high dose phases, respectively, during which adrenergic agonists were administered [4].
Histopathology of kidney tissues using haematoxylin and eosin staining
At the end of experiment right kidneys were removed and tissues for all four groups were sub-
jected to the histopathological process of staining as reported [39, 50].
Histopathology study of the kidney using picrosirus red stain kit
The same preparative procedure given above was repeated for staining with Picrosirus red
(Polyscience, Inc. Germany) as reported [39] and directed by manufacturer.
Preparation of agonists and antagonists
5-methylurapidil (RBI, Natick, MA, USA) is a selective blocker of α1Aadrenoreceptors [51],
chloroethylclonidine (RBI, Natick, MA, USA) a selective blocker of α1Badrenoreceptors [52]
and BMY 7378 (8-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-8-azaspiro(4,5) decane-
7,9-dione dihydrochloride; RBI) a selective blocker of α1D adrenoreceptors [53], were prepared
in saline and kept frozen as stock solutions.
Statistical analysis
The renal vasoconstrictor response to each agonist was taken as the mean of ascending and
descending responses due to four doses which are shown as line graphs as shown in supple-
mentary data. The comparison between the groups considered the overall response calculated
as the mean of the % of drop in renal cortical blood profusion pressure. All data was presented
as mean ± S.E.M. The renal vasoconstrictor data were subjected to a one-way ANOVA fol-
lowed by a Bonferroni post hoc test using GraphPad Prism (GraphPad SoftwareInc., CA, USA)
with significance taken at P< 0.05. The gene expression data was analysed using the compara-
tive method (ΔΔCT method) and using the StepOne™ Software (Version 2.1, Applied Biosys-
tem, USA).
Results
Molecular expression of renal cortical CSE and eNOS
Induction of LVH resulted in a 79% down regulation of eNOS mRNA in the renal cortex com-
pared to that in the control rats. Treatment of LVH with L-arginine resulted in the 510%
increase in eNOS mRNA when compared to LVH groups as shown in Fig 1A
Induction of LVH resulted in a 73% down regulation of CSE mRNA in the renal cortex
compared to its expression in the control rats. Treatment with L-arginine in the Control rats
increased CSE mRNA by 204% compared to the untreated counterpart but had no impact on
the expression levels in the LVH rats as shown in Fig 1B.
NOS enzyme activity in kidney
Ca2+-dependent NOS activity was reduced significantly (all P<0.05) in the kidney of LVH
when compared to the control group while exogenous administration of L-arginine in LVH
significantly increased (all P<0.05) NOS activity when compared to LVH as shown in Fig 1C.
Interaction between NO and renal adrenergic constriction
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Renal and plasma nitric oxide concentrations
Induction of LVH resulted in 45% decrease in renal NO concentrations compared to the con-
trol rats. Treatment with L-arginine resulted in a 236% and 173% increase in renal NO concen-
trations in the Control-NO and LVH-NO groups, respectively as shown in Fig 2A.
Induction of LVH caused a 29% decrease in plasma NO concentration compared to that in
the control rats. Treatment with L-arginine resulted in increased plasma NO concentration of
71% and 52% in the Control-NO and LVH-NO groups, respectively as shown in Fig 2B.
Plasma hydrogen sulphide concentrations
The plasma concentration of H2S was significantly (P<0.05) lower in the LVH group com-
pared to the Control group (16±1 vs.37±1μM) and was unchanged following treatment with L-
arginine compared to LVH (18± vs. 16±1μM) as shown in Fig 2C.
Renal cGMP concentrations
Induction of LVH decreased renal concentrations of cGMP by 84% compared to the control
rats. Treatment with L-arginine increased renal cGMP concentrations by 216% and 163% in
the Control-NO and LVH-NO groups, respectively as shown in Fig 2D.
Fig 1. A, B, C) showing the molecular expression of CSE and eNOS mRNAs and NOS activity in the cortex of kidney of the Control, LVH, Control-
NO and LVH-NO rats. Data is shown as ± SEM while significance is taken as p<0.05.
https://doi.org/10.1371/journal.pone.0189386.g001
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Renal cortical blood perfusion
RCBP was 46% lower (P<0.05) in the LVH compared to the Control rats. Treatment with L-
arginine resulted in a higher RCBP in Control-NO and LVH-NO of some 36% and 47%,
respectively as shown in Fig 2E.
Fig 2. Showing the concentration of nitric oxide in the kidney (A), nitric oxide in plasma(B), H2S in plasma (C), cGMP in the kidney (D) and renal cortical
blood perfusion of Control, LVH, Control-NO and LVH-NO rats. Data is shown as ± SEM while significance is taken as p<0.05.  (P<0.05) vs. Control
group; # (P<0.05) vs. LVH group.
https://doi.org/10.1371/journal.pone.0189386.g002
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Renal vasoconstrictor responses of α1A–adrenorecptors to adrenergic agonists
Noradrenaline. The reductions in renal cortical blood perfusion (RCBP) in the LVH
group were 33% lower in the saline and 37% during the high dose phases of the antagonists
(P<0.05) when compared to same phases in the Control groups of rats. Treatment of LVH
with L-arginine resulted in augmented responses to the α1A–adrenoreceptor agonist NA, by
93% in the saline phase, 76% in low dose 5-MeU phase and 158% in the high dose 5-MeU
phase when compared to respective phases in the LVH group as shown in Fig 3A (S1 Fig).
Phenylephrine. There was a reduced responsiveness to PE in the LVH group, of 27% in
saline and 46% in the high dose phase of 5-MeU (P<0.05) while there was no significant differ-
ence observed during the low dose phase of antagonist when compared to same phases of Con-
trol groups of rats. Treatment of LVH with L-arginine augmented the RCBP responses to PE
by 97% in the saline and 123% in high dose 5-MeU phases when compared to respective phases
of the LVH group as shown in Fig 3B (S2 Fig).
Methoxamine. There was a reduced RCBP responsiveness in the LVH group to ME by
29% in saline phase, 31% in low dose and 43% in high dose 5-MeU phases when compared to
same phases of Control group of rats. Treatment of LVH with L-arginine resulted in aug-
mented responses to ME by 110% in the saline, 91% in low dose phase and 217% in high dose
5-MeU phases (P<0.05) when compared to the respective phases in the LVH group as shown
in Fig 3C (S3 Fig).
Renal vasoconstrictor responses of α1B–adrenorecptors to adrenergic
agonists
Nordrenaline. The responsiveness of RCBP to NA was lower by 47% in the saline, 63% in
low dose and 52% in high dose CEC phases when compared to the same phases in the Control
groups of rats. Treatment of LVH with L-arginine augmented the RCBP responses to NA by
75% in the saline, 116% in the low dose and 75% in the high dose CEC phase compared to
respective phases of the LVH group as shown in Fig 4A (S4 Fig).
Phenylephrine. The RCBP responsiveness to PE was lower by 35% in the saline phase,
36% in low dose and 45% in high dose CEC phases compared to same phases in the Control
groups of rats. Treatment of LVH with L-arginine resulted in augmented RCBP responses PE
by 88% in the saline, 75% in low dose and 79% in the high dose CEC phases compared to the
respective phases of in the LVH group as shown in Fig 4B (S5 Fig).
Methoxamine. There was a blunted RCBP responsiveness to ME by 36% in the saline,
40% in the low dose and 32% in high dose CEC phases when compared to the same phases in
the Control groups of rats. Treatment of LVH with L-arginine resulted in augmented RCBP
responses to ME, by 74% in the saline, 137% in low dose % in high dose CEC phases compared
to the respective phases in the LVH group as shown in Fig 4C (S6 Fig).
Renal vasoconstrictor responses of α1D–adrenorecptors to adrenergic
agonists
Nordrenaline. In the LVH the RCBP responses to NA were lower by 22% in saline and
19% in high dose BMY phase compared to same phases of Control groups of rats. Treatment
of the LVH group with L-arginine augmented the RCBP responses to NA by 65% in the saline,
50% in the low dose and 77% in the high dose BMY phases of when compared to respective
phases of the LVH group as shown in Fig 5A (S7 Fig).
Phenylephrine. Following LVH induction, there were smaller RCBP responses to PE, by
23% in the saline and 33% in the high dose BMY phase compared to the same phases in the
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Control group of rats. Treatment of LVH with L-arginine augmented the RCBP responses to
PE, by 83% in the saline phase, 104% in low dose BMY phase and131% in the high dose BMY
phase compared to respective phases in the LVH group as shown in Fig 5B (S8 Fig).
Methoxamine. There was a reduced RCBP responsiveness in the LVH group to ME, by
26% in saline phase and 46% in high dose BMY phase compared to same phases of Control
group of rats. Treatment of LVH with L-arginine resulted in augmented RCBP responses to
ME, by 68% in the saline phase, 128% in low dose BMY phase and254% in the high dose BMY
phase compared to the respective phases in the LVH group as shown in Fig 5C (S3 Fig).
Histopathological evidence
The kidney tissue did not show any ultra-structural changes in glomerular and tubular compo-
nents in the LVH group except hypercellularity of the glomerulus with increased mesangial
and endothelial cells as shown in Fig 6A and 6B. Treatment with L-arginine in the LVH group
resulted in normal glomerular structures but with a mild atrophy of the tubules. Blood vessels
and parenchyma were normal in LVH-NO as shown in Fig 6C and 6D).
The kidney tissues of all four groups were subjected to PicroSirius red staining and
observed under the polarized light. The collagen content appeared as a red colour as shown in
Fig 6E, 6F and 6H) and collagen in the kidney tissue was quantified by using collagen detection
software (Image+Pro+Plus6.0, ipwin32, USA).Induction of LVH increased the collagen con-
tent, which appeared as plaques around the glomerulus when compared to Control-WKY, as
shown in Fig 6E and 6F. However, treatment with L-arginine diffused the bands and collagen
deposition was reduced to thin threads and appeared as a network around the glomerulus
when compared to the LVH- group as shown in Fig 6G and 6H. Software quantification score
showed collagen deposition in Control, LVH, Control-NO and LVH-NO as 0.6%, 3.8%, 1.4%
and 1.6% respectively.
Discussion
The present study was designed to explore the effect of exogenous administration of an NO
precursor (L-arginine) on the eNOS/NO/cGMP pathway in the kidney of normal and LVH
rats and to investigate whether there was a negative modulatory effect on the CSE/H2S path-
way in the LVH rats. The major hypothesis was that upregulation of the renal eNOS/NO/
cGMP pathway in the kidney would not only prevent the reduced responsiveness in renal cor-
tical blood perfusion but would also tend to normalise the blunted RCBP responses of α1-adre-
noreceptorsto adrenergic agonists the LVH rats.
The findings clearly showed that there was a down regulation of eNOS mRNA in the cortex
of the kidney of the rats given isoprenaline/caffeine to induce LVH and indeed, the NO con-
centration in the renal cortex was lower. A reduced concentration of NO due to decreased
expression of eNOS has previously been reported in the pathological states of hypertension
[54] and LVH [19]. There are a number of possible causes for the reduced NO concentration,
including reduced NO elaboration from eNOS, increased oxidative inactivation of NO and
increased production of vasoconstrictors like endothelin-1 and thromboxane A2 [55, 56]. The
down regulation of eNOS/NO occurs at a time when there is increased production of the vaso-
constrictors noradrenaline and angiotensin II [3, 6,9] in this model of LVH. Nitric oxide
induced vasodilation is followed by an increase in cGMP produced by soluble guanylyl cyclase
Fig 3. Showing the renal vasoconstrictor responses of α1Aadrenoreceptors to NA (3A), PE (3B) and ME (3C) in the
kidney of Control, LVH, Control-NO and LVH-NO rats. Data is shown as ± SEM while significance is taken as
p<0.05.
https://doi.org/10.1371/journal.pone.0189386.g003
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[57] and in the present study this NO-cGMP axis is attenuated as found in other models of car-
diac hypertrophy [58]. Although the down regulation of the eNOS/NO/cGMP was found in
the kidney compartment, the fact that there was also reduced plasma NO concentration sug-
gested that a similar situation pertained globally. This down regulation of the renal eNOS/NO/
cGMP pathway in the LVH rats was associated with an increased renal vascular tone possibly
due to the vasoconstrictor actions of noradrenaline and angiotensin II in the kidney. This
would be supported by reports that Ang II suppressed NO-cGMP production [59] and thus
elevated production of these vasoconstrictors might be responsible for the reduced basal renal
cortical blood pressure in the present study. An attempt was made to provide further evidence
for this view by up regulating the eNOS/NO/cGMP pathway using exogenous administration
of L-arginine as an NO donor, with the aim of counteracting the effect produced by vasocon-
strictors. It was evident that this approach resulted in an increased RCBP, as shown in Figs 2
and 3. Although previous studies have shown that NO increased papillary blood perfusion
[15], the present study demonstrated that this also occurred in the renal cortex as renal cortical
blood perfusion was increased at a time when the eNOS/NO/cGMP pathway was up regulated
in the cortex of the kidney. This would suggest that the buffering action of NO would to a
degree offset the actions of vasoconstrictors. Thus, the buffering action of NO to angiotensin II
enhanced distensibility and increased eNOS/NO/cGMP pathway fit which would contribute
to the increased RCBP.
The responsiveness of α1A-adrenoreceptors to adrenergic agonists was attenuated, but not
blocked, in the LVH model which indicated that the adrenergically mediated renal vasocon-
striction was via α1A-adrenoreceptors which are the predominant subtype in renal resistance
vessels [60]. This decrease in α1A-adrenoreceptor responsiveness may be related to compensa-
tory mechanisms whereby the enhanced sympathetic nervous system activity leads to a down
regulation or desensitization of receptors [61]. Sympathetic nervous activity is elevated in this
model of LVH as reflected by the increased circulating levels of noradrenaline [3, 6]. It should
be pointed out that an increased renal sympathetic nerve activity will also stimulate renin
release and hence raise circulating angiotensin II concentrations. An elevation in both nor-
adrenaline and angiotensin II plasma levels could be responsible for the reduced responsive-
ness of α1A-adrenoreceptors which is similar to that previously reported in a fructose fed rat
model of LVH [62]. An elevated angiotensin II has been found to be responsible for the sup-
pression of NO-cGMP production [59] as observed in the present study and in cardiac hyper-
trophy [58]. In order to provide further support for the role of NO in determining the
responsiveness of α1A-adrenoreceptors to adrenergic agonists, rats were provided with exoge-
nous L-arginine (NO donor) to enhance the eNOS/NO/cGMP signalling cascade. In the LVH
this resulted in heightened vasoconstrictor responses to the α1Aagonists NA, PE and ME even
when the receptors were blocked when compared to the same phases in the LVH group as
shown in Fig 3A, 3B and 3C). These heightened responses were accompanied at the same time
by an up regulation of the eNOS/NO/cGMP pathway in the renal cortex. These findings estab-
lished an association between the up regulated eNOS/NO/cGMP pathway in the renal cortex
and heightened responsiveness of α1A-adrenoreceptors to adrenergic agonists in LVH rats
treated with L-arginine.
The administration of both the low and high doses of CEC, an α1B vadrenoreceptor antago-
nist, had no effect on the renal vasoconstrictor responses to NA and PE in the Control rats.
This was taken to indicate that α1B adrenoreceptors were not functionally contributing to the
Fig 4. Showing the renal vasoconstrictor responses of α1Badrenoreceptors to NA (4A), PE (4B) and ME (4C) in the
kidney of Control, LVH, Control-NO and LVH-NO rats. Data is shown as ± SEM while significance is taken as
p<0.05.
https://doi.org/10.1371/journal.pone.0189386.g004
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renal vasoconstriction. These observations support previous studies [45, 63, 64] which found
that in normal rats with no renal impairment, there was no functional contribution of α1B
adrenoreceptor in mediating the adrenergically induced renal vasoconstriction. However,
there were blunted renal vasoconstrictor responses to ME in the Control rats following both
the low and high dose CEC phases. This pattern of non-responsiveness to NA and PE but not
ME suggested a functional shift of adrenergic receptors with renal vasoconstriction in control
rats being mediated by either α1A or α1D adrenoreceptors. The observation that there was
reduced renal cGMP levels in the LVH rats suggested an alteration in the G-protein 2nd mes-
senger pathway utilized by α1 adrenoreceptors which could be responsible, in part, for reduced
responsiveness of these receptors. This view was supported by showing that exogenous admin-
istration of NO improved renal cGMP levels in the LVH rats consistent with an upregulation
of one of the components of this G-protein 2nd messenger pathway which would contribute to
the augmented responsiveness of α1B adrenoreceptor to NA, PE and ME in both basal states
and following CEC. It is noteworthy that the functional responses of α1B adrenoreceptors to
NA, PE and ME in the LVH-NO group were increased in all three phases when compared to
same phases of LVH.
It was evident that in the LVH, the responsiveness of α1D adrenoreceptor activation by NA,
PE and ME was blunted in the presence of BMY7378. There was a decrease in the magnitude
of responses but they were not completely blocked which indicated a functional contribution
of α1D adrenoreceptors in LVH. In the present study there were 65%, 50% and 77% increases
in the renal vasoconstrictor responsiveness to NA in the saline phase, low and high dose phases
of BMY in the LVH-NO compared to the LVH which strengthens the hypothesis of increased
responsiveness of α1 adrenoreceptor subtypes in LVH after treatment with L-arginine. The
augmented responses of α1D adrenoreceptor activation to adrenergic agonists in the LVH-NO
following blockade with BMY7378 indicated a functional involvement and increased respon-
siveness of this α1D adrenoreceptor subtype in LVH-NO. As PE is a non-selective agonist
for all α1adrenoreceptor subtypes, the fact that in the exogenous administration of PE in
LVH-NO resulted in increased responsiveness to α1D adrenoreceptor activation, by 104% and
131% in the low and high dose BMY7387 phases, respectively, compared to those obtained in
the LVH indicated an enhanced involvement of the α1D adrenoreceptor subtype. However,
administration of the more selective agonist of α1D adrenoreceptor, ME in the LVH-NO group
resulted in augmented responses, of 128% and 254% following blockade with BMY7378 which
indicated that the functional contribution of this adrenergic receptor subtype was elevated
under these conditions.
The exact mechanism by which exogenous administration of L-arginine increased the
responsiveness of α1adrenoreceptors in LVH is not clear but it is likely to be of multifactorial
origin. There is a view arising from a number of other reports that there is an increased contri-
bution from spare receptors [65, 66].An alternative suggestion, arising from the findings is
that exogenous administration of NO donor in LVH up regulated the α1-adrenoreceptors
whereas in pathophysiological states associated with prolonged hyper sympathetic activity, α1-
adrenoreceptors have been reported to be down regulated [67] mostly in the renal vasculature
[68]. Inhibitors of NO increased renal sympathetic nerve activity [69], the observations of the
present study support the concept of a decreased renal sympathetic activity following exoge-
nous administration of NO which could be responsible for the enhanced responsiveness of
α1-adrenoreceptors to the adrenergic agonists in LVH-NO. A limitation of the present study
Fig 5. Showing the overall % drop in renal vasoconstrictor responses of α1D adrenoreceptors to NA (5A), PE (5B) and
ME (5C) in the kidney of Control, LVH, Control-NO and LVH-NO rats. Data is shown as ± SEM while significance is
taken as p<0.05.
https://doi.org/10.1371/journal.pone.0189386.g005
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was that the expression of α1-adrenoreceptors in the kidney was not determined. Nonetheless,
the sensitivity of these receptors was decreased at a time of elevated renal sympathetic activity
in the LVH rats.
More promising evidence for an increased responsiveness was the observations of the mod-
ulation of the eNOS/NO/cGMP pathway which is part of G-protein coupled receptor 2nd mes-
senger pathway system. This system was down regulated in LVH but up regulated following
elevation of the signalling cascade with L-arginine which demonstrated a clear association
between the responsiveness of α1-adrenoreceptors and the level of expression of the eNOS/
NO/cGMP pathway. L-arginine and α1-adrenoreceptors acts through G-protein pathway so it
was assumed that upregulation of cGMP pathway is expected to upregulate or increase the
responsiveness of the α1-adrenoreceptors which are desensitized in LVH and reason for the
selection of L-arginine in this study.
It was apparent that there was an interaction between H2S and NO as there was a negative
impact of the NO donor on renal CSE mRNA expression in LVH rats. These findings contrast
with previous reports [27, 70] which concluded that NO was essential for H2S production but
they are consistent with the suggestion that in normal circumstances where an NO donor
enhances plasma concentrations of H2S but has an insignificant impact on renal expression of
CSE mRNA. This increased H2S production in plasma may be due to other H2S producing
enzymes like cystathione beta synthase (CBS). It is possible to conclude from the present find-
ings that there is an interaction between CSE/H2S and eNOS/NO under normal conditions
but it is abolished in the kidney in LVH. This point of contention is in line with previously
reported study [71].
Conclusion
In summary, the present study explored whether there was a down regulation of eNOS/NO/
cGMP pathway in the kidney of LVH rats. It was found that exogenous administration of a
NO precursor (L-arginine) in LVH not only increased the renal cortical blood perfusion but
also enhanced the blunted responsiveness of α1-adrenoreceptors subtypes to adrenergic ago-
nists by up regulating the eNOS/NO/cGMP pathway in the kidney. We also explored whether
there was an interaction between the CSE/H2S and ENOS/NO cascades under normal condi-
tions but it became apparent that this mutual interaction was abolished in the kidneys of rats
with LVH.
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